Phase I Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Mannan-Binding Lectin
- 9 August 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Clinical Immunology
- Vol. 26 (5), 465-475
- https://doi.org/10.1007/s10875-006-9037-z
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCTGenes & Immunity, 2005
- Altered distribution of mannose-binding lectin alleles at exon I codon 54 in women with vulvar vestibulitis syndromeAmerican Journal of Obstetrics and Gynecology, 2004
- Human Plasma-Derived Mannose-Binding Lectin: A Phase I Safety and Pharmacokinetic StudyScandinavian Journal of Immunology, 2004
- Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humansBiochemical Society Transactions, 2003
- Assays for the Functional Activity of the Mannan-Binding Lectin Pathway of Complement ActivationImmunobiology, 2002
- Mannose‐binding lectin (MBL) therapy in an MBL‐deficient patient with severe cystic fibrosis lung diseasePediatric Pulmonology, 2002
- The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosisJournal of Medical Genetics, 2001
- Mannose binding lectin (MBL) gene mutation is not a risk factor for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in JapaneseGenes & Immunity, 2000
- The human mannose-binding protein functions as an opsonin.The Journal of Experimental Medicine, 1989
- Development and clinical application of electroimmunoassays for the direct quantification of the complement C3 split products C3c and C3dScandinavian Journal of Clinical and Laboratory Investigation, 1984